Overweight and Obesity Among People Living With HIV on Dolutegravir‐ and Efavirenz‐Based Therapies: A Comparative Cross‐Sectional Study
Open Access
- 1 January 2024
- journal article
- research article
- Published by Wiley in AIDS Research and Treatment
- Vol. 2024 (1) , 5347620
Abstract
Background: Overweight and obesity have arisen as major public health challenges, affecting not just the general population but also people living with human immunodeficiency virus (HIV) (PLWH). Obesity and being overweight are both risk factors for heart disease and other related complications. However, little is known in our setting. As a result, this study was conducted to evaluate the prevalence of overweight and obesity and its associated factors among PLWH on dolutegravir (DTG)‐ and efavirenz (EFV)‐based therapies.Methods: An institution‐based comparative cross‐sectional study was carried out from June 30, 2021, to August 30, 2021. We purposively recruited 128 participants who have been on DTG (n = 64)‐ and EFV (n = 64)‐based regimens for ≥ 6 months. Demographic, anthropometric, laboratory, and clinical data were collected using a structured questionnaire. The data were entered into EpiData Version 4.6 and analyzed using SPSS Version 26.0. Multivariable logistic regression was utilized to identify the factors that are associated with being overweight or obese, and the significance level was set at p < 0.05.Result: The prevalence of overweight and obesity was 28.1% in the DTG‐prescribed participants and 15.6% in the EFV‐prescribed participants. Age ≥ 40 years (adjusted odd ratio (AOR) = 3.86; 95% confidence interval (CI): 1.08–13.73; and p = 0.037), cluster of differentiation 4 (CD4) T‐cell counts ≥ 500 cells/mm3 (AOR = 2.95; 95% CI: 1.01–8.59; and p = 0.029), and insufficient physical activity (AOR = 4.6; 95% CI: 1.53–13.84; and p = 0.007) were predictors of overweight and obesity.Conclusion: Overweight and obesity are not uncommon among PLWH on ART. While the difference was statistically insignificant, the prevalence of overweight and obesity was higher in patients treated with DTG compared with those treated with EFV. Older age, higher CD4 cell counts, and insufficient physical activity were associated with overweight and obesity. As a result, healthcare providers must understand the health implications of obesity and consider incorporating targeted weight control programs into standard HIV treatment.Keywords
This publication has 53 references indexed in Scilit:
- Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysiseClinicalMedicine, 2022
- CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and EfavirenzClinical Infectious Diseases, 2020
- Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1New England Journal of Medicine, 2019
- Are new antiretroviral treatments increasing the risks of clinical obesity?Journal of Virus Eradication, 2019
- Health-related quality of life and associated factors in adults living with HIV in RwandaSAHARA-J: Journal of Social Aspects of HIV/AIDS, 2018
- Rising Obesity Prevalence and Weight Gain Among Adults Starting Antiretroviral Therapy in the United States and CanadaAIDS Research and Human Retroviruses, 2016
- Prevalence of a History of Overweight and Obesity in Adolescents With Restrictive Eating DisordersJournal of Adolescent Health, 2015
- The physical activity levels among people living with human immunodeficiency virus/acquired immunodeficiency syndrome receiving high active antiretroviral therapy in RwandaSAHARA-J: Journal of Social Aspects of HIV/AIDS, 2013
- Appropriateness of waist circumference and waist-to-hip ratio cutoffs for different ethnic groupsEuropean Journal of Clinical Nutrition, 2009
- Obesity among Patients with HIV: The Latest EpidemicAIDS Patient Care and STDs, 2008